Evidence map›Paper›PMID 31781887›Full record

ArticleArchives of gynecology and obstetrics2020

Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project.

Amelie De Gregorio, Gabriele Nagel, Peter Möller, Andreas Rempen, Erik Schlicht, Steffen Fritz, Felix Flock, Thorsten Kühn, Falk Thiel, Ricardo Felberbaum and 9 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Archives of gynecology and obstetrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Amelie De GregorioDepartment of Gynecology and Obstetrics, University Hospital Ulm, University of Ulm, Prittwitzstr. 43, 89075, Ulm, Germany. Amelie.degregorio@uniklinik-ulm.de.ORCID http://orcid.org/0000-0001-8273-9906
Gabriele NagelInstitute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.
Peter MöllerInstitute of Pathology, University Hospital Ulm, Ulm, Germany.
Andreas RempenDepartment of Gynecology and Obstetrics, Diakonieklinikum, Schwäbisch-Hall, Germany.
Erik SchlichtDepartment of Gynecology and Obste, Kliniken Ostalb, Mutlangen, Germany.
Steffen FritzDepartment of Gynecology and Obstetrics, Sanaklinikum, Biberach, Germany.
Felix FlockDepartment of Gynecology and Obstetrics, Hospital Memmingen, Memmingen, Germany.
Thorsten KühnDepartment of Gynecology and Obstetrics, Hospital Esslingen, Esslingen am Neckar, Germany.
Falk ThielDepartment of Gynecology and Obstetrics, Hospital Eichert, Göppingen, Germany.
Ricardo FelberbaumDepartment of Gynecology and Obstetrics, Hospital Kempten, Kempten, Germany.
Florian EbnerDepartment of Gynecology and Obstetrics, Amper Hospital, Dachau, Germany.
Nikolaus De GregorioDepartment of Gynecology and Obstetrics, University Hospital Ulm, University of Ulm, Prittwitzstr. 43, 89075, Ulm, Germany.
Thomas Wolfram Paul FriedlDepartment of Gynecology and Obstetrics, University Hospital Ulm, University of Ulm, Prittwitzstr. 43, 89075, Ulm, Germany.
Lisa WiesmüllerDepartment of Gynecology and Obstetrics, University Hospital Ulm, University of Ulm, Prittwitzstr. 43, 89075, Ulm, Germany.
Peter KuhnComprehensive Cancer Center, University Hospital Ulm, Ulm, Germany.
Margit SchmittDepartment of Gynecology and Obstetrics, University Hospital Ulm, University of Ulm, Prittwitzstr. 43, 89075, Ulm, Germany.
Wolfgang JanniDepartment of Gynecology and Obstetrics, University Hospital Ulm, University of Ulm, Prittwitzstr. 43, 89075, Ulm, Germany.
Dietrich RothenbacherInstitute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.
Jens HuoberDepartment of Gynecology and Obstetrics, University Hospital Ulm, University of Ulm, Prittwitzstr. 43, 89075, Ulm, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLarge translational research projects may contribute to further progress in cancer treatment by exploring molecular biology, immunologic approaches and identification of new prognostic and predictive factors. Therefore, the BRandOBio-project combines a clinical registry for collection of patient and tumor characteristics with a biobank comprising tumor and liquid biopsies. In addition, sociodemographic, environmental and lifestyle factors of included patients with primary newly diagnosed breast or ovarian cancer, other rare malignant ovarian tumors or gestational trophoblastic disease are prospectively collected.

methodsThe target population includes the German "Alb-Allgäu-Bodensee Region" which constitutes the outreach area of the University Hospital Ulm with affiliated academic centers and private practices. Clinical data combined with primary tumor tissue samples and longitudinal repeatedly collected blood samples [before, 6 (in high-risk situations), 12, 36 and 60 months after treatment and at relapse] will be acquired from more than 4000 patients within the next years. Standardized questionnaires are given to patients of the University Hospital Ulm and eight selected external sites for assessing life style and cancer risk factors. Concomitantly, storage of paraffin-embedded tumor samples as well as liquid biopsy samples will allow translational research projects, for example in terms of investigating circulating DNA and germ line DNA from cell pellets.

resultsStarting in January 2016 at the University Hospital Ulm, 19 additional external sites started recruiting patients in March 2017. As of September 15th 2019, 2151 patients with newly diagnosed cancers could be recruited (2044 breast cancer; 107 ovarian cancer). Nearly all patients provided biological samples (tumor and liquid biopsy) and about 80% returned the standardized questionnaire. After 1 year follow-up, blood samples were available from more than 80% of the participating patients.

conclusionsThe BRandO BIO study is a large prospective cohort study with integrated comprehensive biobank and evaluation of sociodemographic and life style factors of gynecological cancer patients in a well-defined geographical area in the South West of Germany. Continuous high patient recruitment and stable rates over 80% for returned questionnaires as well as for repeated blood sampling show high acceptance of the BRandO study program and confirms feasibility of the project.

Indexed as

AdultBiological Specimen BanksBreast NeoplasmsFeasibility StudiesFemaleHumansMiddle AgedOvarian NeoplasmsPrognosisProspective StudiesRisk FactorsTranslational Research, BiomedicalBiobankBreast cancerCirculating tumor DNAClinical registryEpidemiologyOvarian cancerTranslational research

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.